Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Regional Distribution of Nitric Oxide Synthase in Human Anorectal Tissue: A Pilot Study on the Potential Role for Nitric Oxide in Haemorrhoids

Author(s): Varut Lohsiriwat*, Vincent G. Wilson, John H. Scholefield and Michael R. Dashwood

Volume 18, Issue 1, 2020

Page: [43 - 49] Pages: 7

DOI: 10.2174/1570161116666180730101532

Price: $65

Abstract

Objective: To study the distribution of nitric oxide synthase (NOS) isoforms and protein levels in human haemorrhoids and rectal tissue.

Methods: Protein expression of NOS1, NOS2 and NOS3 was compared between haemorrhoids (n=14) and normal rectal submucosa (n=6) using Western blot analysis. The localisation of all NOS isoforms to specific structures was determined by immunohistochemistry.

Results: Western blot analysis showed median (interquartile range) protein levels of all NOS isoforms were 1.5-2.4 times higher in haemorrhoids than rectal tissue; 121.4 (55.2-165.5) vs 50.0 (25.5-73.7) for NOS1 (p=0.020), 32.2 (23.8-140.6) vs 14.8 (9.6-34.0) for NOS2 (p=0.109), and 80.1 (62.0-139.5) vs 54.3 (48.7 -61.7) for NOS3 (p=0.015). Immunohistochemistry revealed a different distribution and location of all NOS isoforms in vascular and non-vascular structure of haemorrhoids and rectal tissues. The number of haemorrhoid specimens showing positive immunoreactivity of NOS in the vascular endothelium was significantly higher than that in rectal tissue for NOS1 (11/14 (79%) vs 1/6 (17%); p=0.018) and NOS3 (8/14 (57%) vs 0/6 (0%); p=0.042), but not for NOS2 (6/14 (43%) vs 4/6 (67%); p=0.63).

Conclusion: Haemorrhoids have significantly higher protein levels of NOS1 and NOS3 than rectal tissue. The vascular endothelium of haemorrhoids also has significantly higher positive immunoreactivity of NOS1 and NOS3 than rectal tissue suggesting that blood vessels in haemorrhoids are exposed to higher NO concentrations than those of rectal tissue. Since haemorrhoids exhibit marked vascular dilatation and present with bleeding or swelling, a reduction in NOS - by applying NOS inhibitors - may potentially improve the symptoms of haemorrhoids.

Keywords: Nitric oxide synthase, nitric oxide, haemorrhoids, rectum, anus, blood vessels.

« Previous Next »
Graphical Abstract

[1]
Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol 2012; 18: 2009-17.
[2]
Aigner F, Gruber H, Conrad F, et al. Revised morphology and hemodynamics of the anorectal vascular plexus: Impact on the course of hemorrhoidal disease. Int J Colorectal Dis 2009; 24: 105-13.
[3]
Chung YC, Hou YC, Pan AC. Endoglin (CD105) expression in the development of haemorrhoids. Eur J Clin Invest 2004; 34: 107-12.
[4]
Han W, Wang ZJ, Zhao B, et al. Pathologic change of elastic fibers with difference of microvessel density and expression of angiogenesis-related proteins in internal hemorrhoid tissues. Zhonghua Wei Chang Wai Ke Za Zhi 2005; 8: 56-9.
[5]
Lohsiriwat V. Approach to hemorrhoids. Curr Gastroenterol Rep 2013; 15: 332.
[6]
Lohsiriwat V, Scholefield JH, Wilson VG, Dashwood MR. Endothelin-1 and its receptors on haemorrhoidal tissue: A potential site for therapeutic intervention. Br J Pharmacol 2017; 174: 569-79.
[7]
Hsieh NK, Chang HR, Hu CT, Chen HI. Effects of nitric oxide donor and nitric oxide synthase inhibitor on the resistance, exchange and capacitance functions of the canine intestinal vasculature. Vascul Pharmacol 2008; 48: 122-8.
[8]
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
[9]
Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
[10]
Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014; 20: 2555-63.
[11]
Kubes P. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation 1995; 2: 235-44.
[12]
Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999; 26: 269-71.
[13]
Petersson J, Schreiber O, Steege A, et al. eNOS involved in colitis-induced mucosal blood flow increase. Am J Physiol Gastrointest Liver Physiol 2007; 293: 1281-7.
[14]
Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998; 101: 731-6.
[15]
Du X, Ou X, Song T, et al. Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells. Exp Biol Med 2015; 240: 1472-9.
[16]
Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 2009; 32: 1103-8.
[17]
Bevers LM, Braam B, Post JA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 2006; 47: 87-94.
[18]
Dashwood MR, Savage K, Dooley A, Shi-Wen X, Abraham DJ, Souza DS. Effect of vein graft harvesting on endothelial nitric oxide synthase and nitric oxide production. Ann Thorac Surg 2005; 80: 939-44.
[19]
Desrois M, Caus T, Dalmasso C, Lan C, Cozzone PJ, Bernard M. Expression of the three nitric oxide synthase isoforms and nitric oxide level in the rat heart during cold storage and blood reperfusion. Cell Mol Biol 2009; 55: 1208-14.
[20]
Huang YQ, Xiao SD, Zhang DZ, Mo JZ. Nitric oxide synthase distribution in esophageal mucosa and hemodynamic changes in rats with cirrhosis. World J Gastroenterol 1999; 5: 213-6.
[21]
Aigner F, Bodner G, Gruber H, et al. The vascular nature of hemorrhoids. J Gastrointest Surg 2006; 10: 1044-50.
[22]
Salvemini D, Wang ZQ, Wyatt PS, et al. Nitric oxide: A key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 1996; 118: 829-38.
[23]
Ferrer-Sueta G, Radi R. Chemical biology of peroxynitrite: kinetics, diffusion, and radicals. ACS Chem Biol 2009; 4: 161-77.
[24]
Castaneda AA, Denning JW, Chang L, Mercer DW. Does upregulation of inducible nitric oxide synthase (iNOS) render the stomach more susceptible to damage? J Surg Res 1999; 84: 174-9.
[25]
Gray GA, Schott C, Julou-Schaeffer G, Fleming I, Parratt JR, Stoclet JC. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol 1991; 103: 1218-24.
[26]
Leite PF, Danilovic A, Moriel P, et al. Sustained decrease in superoxide dismutase activity underlies constrictive remodeling after balloon injury in rabbits. Arterioscler Thromb Vasc Biol 2003; 23: 2197-202.
[27]
Comtois AS, Barreiro E, Huang PL, Marette A, Perrault M, Hussain SN. Lipopolysaccharide-induced diaphragmatic contractile dysfunction and sarcolemmal injury in mice lacking the neuronal nitric oxide synthase. Am J Respir Crit Care Med 2001; 163: 977-82.
[28]
Loesch A, Belai A, Burnstock G. An ultrastructural study of NADPH-diaphorase and nitric oxide synthase in the perivascular nerves and vascular endothelium of the rat basilar artery. J Neurocytol 1994; 23: 49-59.
[29]
Hilgers RH, Todd J, Webb RC. Regional heterogeneity in acetylcholine-induced relaxation in rat vascular bed: Role of calcium-activated K+ channels. Am J Physiol Heart Circ Physiol 2006; 291: 216-22.
[30]
Steiling K, Ryan J, Brody JS, Spira A. The field of tissue injury in the lung and airway. Cancer Prev Res 2008; 1: 396-403.
[31]
Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997; 17: 1846-58.
[32]
Eissa NT, Strauss AJ, Haggerty CM, Choo EK, Chu SC, Moss J. Alternative splicing of human inducible nitric-oxide synthase mRNA. tissue-specific regulation and induction by cytokines. J Biol Chem 1996; 271: 27184-7.
[33]
Cunha IW, Lopes A, Falzoni R, Soares FA. Sarcomas often express constitutive nitric oxide synthases (NOS) but infrequently inducible NOS. Appl Immunohistochem Mol Morphol 2006; 14: 404-10.
[34]
Ito Y, Ohkubo T, Asano Y, et al. Nitric oxide production during cerebral ischemia and reperfusion in eNOS- and nNOS-knockout mice. Curr Neurovasc Res 2010; 7: 23-31.
[35]
Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 1998; 95: 4888-93.
[36]
Moore PK, Handy RL. Selective inhibitors of neuronal nitric oxide synthase--is no NOS really good NOS for the nervous system? Trends Pharmacol Sci 1997; 18: 204-11.
[37]
Kielstein A, Tsikas D, Galloway GP, Mendelson JE. Asymmetric dimethylarginine (ADMA)--a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007; 17: 55-9.
[38]
Ormerod AD, Copeland P, Shah SA. Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. Br J Dermatol 2000; 142: 985-90.
[39]
Goldsmith PC, Leslie TA, Hayes NA, Levell NJ, Dowd PM, Foreman JC. Inhibitors of nitric oxide synthase in human skin. J Invest Dermatol 1996; 106: 113-8.
[40]
Segarra G, Cortina B, Mauricio MD, et al. Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis. World J Gastroenterol 2016; 22: 10545-56.
[41]
Hernandez-Bernal F, Castellanos-Sierra G, Valenzuela-Silva CM, et al. Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3). World J Gastroenterol 2014; 20: 1594-601.
[42]
MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996; 11: 2449-52.
[43]
Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003; 63: 71-100.

Rights & Permissions Print Cite
Article Metrics
21
3
© 2024 Bentham Science Publishers | Privacy Policy